SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo
- 1 August 2014
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 351 (1), 143-150
- https://doi.org/10.1016/j.canlet.2014.05.012
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung CancerJournal of Thoracic Oncology, 2012
- Detection of Hepatocyte Growth Factor (HGF) Ligand-c-MET Receptor Activation in Formalin-Fixed Paraffin Embedded Specimens by a Novel Proximity AssayPLOS ONE, 2011
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2Clinical Cancer Research, 2010
- Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene AddictionScience Signaling, 2009
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoMolecular Cancer Therapeutics, 2009
- Drug development of MET inhibitors: targeting oncogene addiction and expedienceNature Reviews Drug Discovery, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Stromal fibroblasts in cancer initiation and progressionNature, 2004
- Series Introduction: Invasive growth: from development to metastasisJCI Insight, 2002